高通量核苷酸测序在风湿病学中的使用现状
该研究通过半自动化文献综述和公共序列读存档检索,评估了高通量测序(HTS)在风湿病研究中的使用情况及公共HTS数据的可获取性。在699篇鉴定文章中,类风湿关节炎(182篇,26%)、系统性红斑狼疮(161篇,23%)和骨关节炎(152篇,22%)是HTS检测报告最多的风湿病,RNA-Seq(457篇,65%)是最常用的检测方法。研究指出测序患者伴随临床特征的质量差异巨大,并提出了风湿病相关HTS数据所需的最小临床数据集。
要点
- 类风湿关节炎、系统性红斑狼疮和骨关节炎是HTS应用报告最多的风湿病。
- RNA-Seq是最常用的HTS检测方法,主要用于血液或滑膜组织的生物标志物鉴定。
- 测序患者伴随临床特征的质量差异显著,需讨论标准化报告以促进临床有意义的使用。
核心结论
- HTS可同时分析许多样本的广泛分子特征,在风湿病患者的新型个体化诊断和治疗策略中具有巨大潜力。
- 风湿病即将成为HTS的第三大疾病领域,尤其是RNA-Seq检测,但需开始讨论伴随风湿病相关HTS数据的临床特征报告以使其具有临床意义。
研究设计与样本
- 在PubMed上进行半自动化文献综述,包括R脚本和人工整理,并在序列读存档中手动搜索公开可用的HTS数据。
主要发现
- 在699篇鉴定文章中,类风湿关节炎(n=182篇出版物,26%)、系统性红斑狼疮(n=161,23%)和骨关节炎(n=152,22%)是HTS检测报告最多的风湿病。
- 最常报告的检测是RNA-Seq(n=457,65%),用于鉴定血液或滑膜组织中的生物标志物。
- 测序患者伴随临床特征的质量差异巨大,研究提出了风湿病相关HTS数据所需的最小临床数据集。
临床怎么用
- 临床医生应关注HTS在风湿病个体化诊疗中的潜在应用,尤其是RNA-Seq检测。
- 在利用风湿病相关HTS数据时,需注意其伴随临床特征的标准化报告,以支持临床 meaningful 的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Here, we assess the usage of high throughput sequencing (HTS) in rheumatic research and the availability of public HTS data of rheumatic samples. METHODS: We performed a semiautomated literature review on PubMed, consisting of an R-script and manual curation as well as a manual search on the Sequence Read Archive for public available HTS data. RESULTS: Of the 699 identified articles, rheumatoid arthritis (n=182 publications, 26%), systemic lupus erythematous (n=161, 23%) and osteoarthritis (n=152, 22%) are among the rheumatic diseases with the most reported use of HTS assays. The most represented assay is RNA-Seq (n=457, 65%) for the identification of biomarkers in blood or synovial tissue. We also find, that the quality of accompanying clinical characterisation of the sequenced patients differs dramatically and we propose a minimal set of clinical data necessary to accompany rheumatological-relevant HTS data. CONCLUSION: HTS allows the analysis of a broad spectrum of molecular features in many samples at the same time. It offers enormous potential in novel personalised diagnosis and treatment strategies for patients with rheumatic diseases. Being established in cancer research and in the field of Mendelian diseases, rheumatic diseases are about to become the third disease domain for HTS, especially the RNA-Seq assay. However, we need to start a discussion about reporting of clinical characterisation accompany rheumatological-relevant HTS data to make clinical meaningful use of this data.
引用
- Boegel S, Castle JC, Schwarting A, et al. Current status of use of high throughput nucleotide sequencing in rheumatology. RMD Open. 2021. PMID: 33408124. doi:10.1136/rmdopen-2020-001324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。